In a welcome move, AnaptysBio saw its Relative Strength Rating rise from 61 to 74 on Thursday.
Can You Really Time The Stock Market?
IBD's unique RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an RS Rating of over 80 in the early stages of their moves. See if AnaptysBio can continue to show renewed price strength and hit that benchmark.
AnaptysBio is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could spark a new run.
The company reported 0% EPS growth in its most recent report, while sales growth came in at 287%. Look for the next report on or around Aug. 11.
AnaptysBio holds the No. 137 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Harmony Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
